奥氮平与喹硫平联合治疗精神分裂症对患者血脂代谢及激越行为的影响

Effects of Olanzapine and Quetiapine Combined Treatment on Blood Lipid Metabolism and Agitation in Patients with Schizophrenia

目的:探讨奥氮平与喹硫平联合治疗对精神分裂症(SCH)患者血脂代谢及激越行为的影响。方法:按随机数字表法将本院2019年8月—2021年1月期间接诊的SCH患者80例分为对照组(n=40)和观察组(n=40)。对照组口服奥氮平治疗,观察组加用喹硫平治疗,持续用药8周。比较两组临床疗效、血脂代谢、激越行为和不良反应情况。结果:治疗总有效率观察组为95.00%,较对照组的80.00%高,有统计学差异(P<0.05);观察组治疗后密度脂蛋白胆固醇(HDL-C)高于对照组,有统计学差异(P<0.05);观察组治疗后阳性与阴性症状量表(PANSS)、激越因子评分表(PANSS-EC)评分较对照组低,有统计学差异(P<0.05);两组不良反应相比,无统计学差异(P>0.05)。结论:奥氮平联合喹硫平治疗SCH可更好地改善激越行为,减小对血脂代谢影响,安全可靠,值得广泛应用。

Objective:To investigate the effect of olanzapine combined with quetiapine on blood lipid metabolism and agitation in patients with schizophrenia(SCH).Methods:According to the random number table method,80 SCH patients admitted in our hospital from August 2019 to January 2021 were divided into control group(n=40)and observation group(n=40).The control group was treated with olanzapine orally,and the observation group was treated with quetiapine for 8 weeks.The clinical efficacy,lipid metabolism,agitation and adverse reactions of the two groups were compared.Results:The total effective rate in the observation group was 95.00%,higher than 80.00%in the control group(P<0.05).After treatment,the density lipoprotein cholesterol(HDL-C)in observation group was higher than that in control group,and the difference was statistically significant(P<0.05).After treatment,positive and negative symptom Scale(PANSS)and agitation factor Score(PANSS-EC)in the observation group were lower than those in the control group(P<0.05).There was no statistical difference in adverse reactions between the two groups(P>0.05).Conclusion:Olanzapine combined with quetiapine can enhance the therapeutic effect of SCH,improve the agitation behavior of patients,and has little effect on the body's blood lipid metabolism.It is safe and reliable,and is worthy of wide application.